The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

  • Oleen-Burkey M
  • Dor A
  • Castelli-Haley J
 et al. 
  • 12

    Readers

    Mendeley users who have this article in their library.
  • 17

    Citations

    Citations of this article.

Abstract

OBJECTIVE: To examine how changes in the medication possession ratio (MPR) affect the probability of multiple sclerosis (MS) relapses and total and MS-related charges among patients treated with glatiramer acetate (GA).

METHODS: Data were obtained from i3 InVision™ Data Mart for January 1, 2006 through March 31, 2010. Patients were included if they were diagnosed with MS, initiated therapy with GA, and had continuous insurance coverage from 6 months prior through 24 months after initial use of GA (n=839). Multivariate regressions which controlled for patient characteristics examined the association between achievement of alternative MPR goals and patient relapses and charges.

RESULTS: Patients who achieved an MPR of at least 0.7 had significantly lower odds of relapse than those with MPR thresholds below 0.7, with achievement of a threshold of 0.7, 0.8, or 0.9, associated with an odds ratio of relapse of 0.545 (95% CI=0.351-0.824), 0.568 (95% CI=0.371-0.870), and 0.421 (95% CI=0.260-0.679), respectively. Attaining higher MPR thresholds resulted in larger reductions in direct medical charges, excluding GA and other MS-related drugs. MPR of 0.25 was associated with $1699 lower 2-year total direct medical charges (p=0.009) while a threshold of 0.95 was associated with $2136 lower total charges (p
LIMITATIONS: Results are generalizable only to patients with medical and prescription benefit coverage without regard for functional status.

CONCLUSIONS: As adherence improved the odds of relapse decreased and charge offsets generally increased. Results suggest that, despite higher costs associated with increased usage of GA, patient outcomes are improved and there are cost-offsets associated with adherent use of GA.

Author-supplied keywords

  • Adult
  • Costs and Cost Analysis
  • Drug Utilization
  • Fees
  • Female
  • Health Services
  • Health Services: economics
  • Health Services: utilization
  • Humans
  • Immunosuppressive Agents
  • Immunosuppressive Agents: administration & dosage
  • Immunosuppressive Agents: economics
  • Immunosuppressive Agents: therapeutic use
  • Male
  • Medication Adherence
  • Medication Adherence: statistics & numerical data
  • Middle Aged
  • Multiple Sclerosis
  • Peptides
  • Peptides: administration & dosage
  • Peptides: economics
  • Peptides: therapeutic use
  • Pharmaceutical
  • Pharmaceutical: statistics & numerical data
  • Recurrence
  • Relapsing-Remitting
  • Relapsing-Remitting: drug ther
  • Retrospective Studies

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • M A Oleen-Burkey

  • A Dor

  • J Castelli-Haley

  • M J Lage

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free